HNRNPA1 and gastric cancer: hnRNPA1 knockdown in GCSCs prevents this effect; thus, targeting the exo-lncFERO/hnRNPA1/SCD1 axis combined with chemotherapy might prove to be a promising CSC-based strategy for GC treatment [72] (Fig. 2).